Faculty Directory

William M. Baldwin, III, M.D., Ph.D. | Staff

Area of Interest:
Cardiac and renal allograft rejection, vascular inflammation, innate immune responses.

Robert L. Fairchild, Ph.D. | Staff

Area of Interest:
Skin disease, Skin and cardiac allograft rejection, T cell recruitment to inflammation in peripheral tissues

James H. Finke, Ph.D. | Staff

Area of Interest:
Tumor immunity, T lymphocytes, signal transduction and transcription factors

Brian Gastman, M.D. | Staff

Area of Interest:
Tumor Immunology, Cancer Therapy Resistance.

Neetu Gupta, Ph.D. | Assistant Staff

Area of Interest:
Spatial organization and dynamics of B cell activation during an immune response

Trine Jorgensen, Ph.D. | Assistant Staff

Area of Interest:
Autoimmunity; Systemic lupus erythematosus; Gender differences; The role of interferons in autoimmunity

Thomas A. Hamilton, Ph.D. | Chair

Area of Interest:
Analysis of mechanisms regulating inflammatory gene expression in mononuclear phagocytes. Analysis of stimulus-dependent control of chemokine and cytokine mRNA stability.

Xiaoxia Li, Ph.D. | Staff

Area of Interest:
Signal transduction in innate and adaptive immunity

Lina Lu, M.D. | Associate Staff

Area of Interest:
Liver dendritic cells regulate hepatic immunity; Immunosuppressive activity of hepatic stellate cells

Feng Lin Ph.D. | Associate Staff

Area of Interest:
The complement system is an important part of the innate immunity. Complement activation products not only directly help to eliminate invading pathogens, but also participate in many immunological reactions, including clearance of immune complexes, antibody production, and T-cell regulation.

Booki Min, D.V.M., Ph.D. | Associate Staff

Area of Interest:
T cell homeostasis, Memory T cells, Role of basophils in adaptive immunity.

Gregory Plautz M.D. | Staff

Area of Interest:
Our laboratory studies strategies to optimize the immune response to tumors for therapeutic purposes. We have found that we can sensitize T cells to weak tumor antigens in vaccine-draining lymph nodes and then purify recently stimulated T cells. These T cells can be activated in vitro to proliferate and acquire effector function and treat established tumor following adoptive transfer. We are currently working with a transgenic mouse model of HER2/neu breast cancer to define tumor-rejection antigens on cancer stem cells.

Shiguang Qian, Ph.D. | Associate Staff

Area of Interest:
Transplantation Tolerance; Transplant Rejection; Liver Immunity; Dendritic Cell Biology; Co-stimulation; Transplant Microsurgery

Vincent Tuohy, Ph.D. | Staff

Area of Interest:
Autoimmunity, Immunoregulation, T Cells, Gene Therapy

Anna Valujskikh, Ph.D. | Associate Staff

Area of Interest:
Transplant Immunology;Memory T Cells; T Cell Costimulation